Longeveron在2024年CHSS年会上介绍了HLHS细胞治疗的5年生存数据。 Longeveron presents 5-year survival data for HLHS cell-based therapy at CHSS Annual Meeting in 2024.

Longeveron Inc.将在2024年10月27日至28日在芝加哥举行的CHSS年会上介绍其ELPIS I关于Hypollatic Left Hearts综合症(HLHS)细胞疗法研究的五年生存数据。 Longeveron Inc. will present five-year survival data from its ELPIS I study on cell-based therapy for Hypoplastic Left Heart Syndrome (HLHS) at the CHSS Annual Meeting on October 27-28, 2024, in Chicago. HLHS是一种罕见的先天性心脏病,每年影响约1,000名美国婴儿,往往需要复杂的手术。 HLHS is a rare congenital heart defect affecting about 1,000 U.S. infants annually, often requiring complex surgeries. 该公司的调查产品Lomecel-BTM旨在提高无移植存活率。 The company's investigational product, Lomecel-B™, aims to improve transplant-free survival rates.

文章

GlobeNewswire

WallStreet Online

TMCnet

-- 显示更少 --

延伸阅读

相关故事